pain. Analgesic, antipyretic and anti-inflammatory drug, unspecified
Conditions
Interventions
Intervention 1: Group1: injection of 2.48 mmol (60 mg) intravenous magnesium sulfate diluted in 2 mL of saline before injection of etomidate. Intervention 2: Group2: injection of 30 mg of lidocaine 1%
Prevention
Placebo
Group1: injection of 2.48 mmol (60 mg) intravenous magnesium sulfate diluted in 2 mL of saline before injection of etomidate
Group2: injection of 30 mg of lidocaine 1% diluted in 2 ml of saline before injection of etomidate .
Group3: injection of 5 ml of saline before injection of etomidate.
Sponsors
Vice chancellor For Research Of Ahvaz Jondishapour University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age range 18-60; Patients undergoing surgery with The anesthetic etomidate except for cesarean section. Exclusion criteria: Neuromuscular diseases; Heart disease; Epilepsy; pregnancy; Receiving pain medications in twenty-four hours before surgery; Thrombophlebitis; Neurological and psychiatric disorders.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: After injection of etomidate and during twenty-four hours after surgery. Method of measurement: 4 point Ambesh scal. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactJamileh Leilaten
Ahvaz Jondishapour University of Medical Sciences
Outcome results
None listed